REDWOOD CITY, Calif., Feb 03, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, is excited to announce that it is one of only eight companies selected to present at the 2nd Annual Innovation Showcase during the American Stroke Association 2023 International Stroke Conference (ISC), being held in Dallas, TX. The showcase is being co-hosted by ISC in collaboration with both the National Heart, Lung, and Blood Institute and the National Institute for Neurological Disorders and Stroke (NINDS).
The Company will present during the Scientific Sessions on Thursday, February 9 between 3:30 PM and 5:00 PM Central, located in Learning Studio I in the Exhibit Hall area of the Dallas Convention Center in Dallas, TX.
Biotricity will be presenting its ongoing work on stroke prediction in CKD patients, supported by its recent NIH grant. The ongoing research is focused on optimizing the company’s AI for predictive stroke analytics in patients with chronic kidney disease (CKD). Real-time monitoring of stroke risk in CKD patients, and in particular those undergoing dialysis, is likely to influence adopted therapeutic strategies and promote a more personalized therapeutic approach. Better care and prevention through monitoring of these high-risk patients is expected to reduce mortality rates and the high per-capita cost of treatment, which is currently five-times higher than the average healthcare spend.
Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, “We are excited to be working on this critically important project with the NIH, further validating our current AI technology and expanding into predictive monitoring and a new disease profile. The completion of this work will pave the road for AI-based predictive analytics in CKD patients and potentially ones with other chronic diseases.”
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts:
Investor relations:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
(212) 896-1254
Investors@biotricity.com
